DSGNDesign Therapeutics, Inc.

Nasdaq designtx.com


$ 4.69 $ 0.00 (0 %)    

Wednesday, 08-May-2024 15:59:55 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 4.69
$ 4.74
$ 4.68 x 400
$ 0.00 x 0
$ 4.58 - $ 5.22
$ 1.94 - $ 8.47
1,282,843
na
264.93M
$ 1.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-19-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 design-therapeutics-q1-eps-020-beats-029-estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $...

 piper-sandler-upgrades-design-therapeutics-to-overweight-raises-price-target-to-12

Piper Sandler analyst Yasmeen Rahimi upgrades Design Therapeutics (NASDAQ:DSGN) from Neutral to Overweight and raises the pr...

 design-therapeutics-and-2-other-stocks-under-5-insiders-are-buying

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confid...

 rbc-capital-reiterates-sector-perform-on-design-therapeutics-maintains-4-price-target

RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and maintains $4 pric...

 wedbush-reiterates-neutral-on-design-therapeutics-maintains-5-price-target

Wedbush analyst Laura Chico reiterates Design Therapeutics (NASDAQ:DSGN) with a Neutral and maintains $5 price target.

 design-therapeutics-outlines-progress-across-genetac-platform

New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profi...

 design-therapeutics-q4-eps-021-beats-031-estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $...

 earnings-scheduled-for-march-19-2024

Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per...

 rbc-capital-maintains-sector-perform-on-design-therapeutics-lowers-price-target-to-4

RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and lowers the price t...

 design-therapeutics-q3-eps-028-beats-041-estimate

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $...

 over-5m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-aggressively-buying

The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or conc...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 210 companies reached new 52-week lows.

 market-sentiment-teeters-as-us-indices-including-sp-500-break-key-supports-next-levels-to-watch

All three leading U.S. stock indices — the S&P 500, Nasdaq 100, and Russell 2000 — have simultaneously breached a crucial t...

 design-therapeutics-modified-dt-216-may-have-potential-but-analyst-awaits-further-developments

RBC Capital Market downgraded Design Therapeutics Inc (NASDAQ: DSGN) from Outperform to Sector Perform with a price target of $7, 

 nasdaq-falls-100-points-siyata-mobile-shares-spike-higher

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow trad...

 why-phenomex-are-trading-lower-by-around-20-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION